ArticleScientific reports2026
Translational evaluation of BUB1B as a precision medicine biomarker for hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BUB1B is a novel prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, characterized by late-stage diagnosis and poor prognosis due to insufficient biomarkers for early detection and personalized therapy. This study comprehensively investigated BUB1B, a spindle assembly checkpoint component, as a precision medicine biomarker in HCC through integrative multi-omics analysis and clinical validation. Pan-cancer analysis using The Cancer Genome Atlas (TCGA) revealed significant BUB1B upregulation across 19 tumor types, with robust overexpression in HCC (P < 0.05). High BUB1B expression independently predicted poor overall survival (hazard ratio = 1.39, 95% confidence interval: 1.20–1.63, P < 0.001) and correlated with tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, Ki-67 index, and alpha-fetoprotein (AFP) levels. BUB1B expression strongly associated with genomic instability markers including homologous recombination deficiency and microsatellite instability (all P < 0.001). Immune profiling revealed paradoxical enrichment of activated T cells yet elevated Tumor Immune Dysfunction and Exclusion (TIDE) scores (P < 0.001), suggesting immune escape and potential resistance to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. Drug sensitivity analysis identified high BUB1B expression as predictive of enhanced sensitivity to sorafenib, paclitaxel, and doxorubicin. Clinical validation in an independent cohort confirmed BUB1B overexpression, cytoplasmic localization, and association with worse survival (P = 0.044). Mechanistic studies using selective BUB1B inhibitors demonstrated comprehensive mitogen-activated protein kinase (MAPK) pathway regulation, with significant suppression of HRAS (60% reduction), extracellular signal-regulated kinase 1/2 (ERK1/2) (40–60% reduction), and p38 isoforms (30–60% reduction) (all P < 0.05).These findings establish BUB1B as a clinically actionable biomarker for risk stratification and precision therapeutics in HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.